Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sunflower State Newswire.
Press releases published on April 29, 2025
InVitria Launches OptiLeukin 2: A Chemically Defined Recombinant IL-2 for Cell Therapy
EIN Presswire
·
April 29, 2025
Animal- and bacteria-free recombinant IL-2 enables safer, scalable immune cell expansion for CAR-T, NK, and iPSC-derived cell therapy workflows. JUNCTION CITY, KS, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- InVitria Launches OptiLeukin™ 2: A …
InVitria Unveils Optibumin 25: First Recombinant 25% Human Serum Albumin for Closed-System Biomanufacturing
EIN Presswire
·
April 29, 2025
Recombinant alternative to plasma-derived HSA enables safer, scalable, closed-system cell …
PromptCare Introduces New Infusion Suite in Wichita, Kansas
EIN Presswire
·
April 29, 2025
New location offers on-site infusion therapy in comfortable, private space for pediatric and adult patients managing rare and chronic conditions WICHITA, KS, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- PromptCare announces today the grand …
Crystal Structures Glazing Company Enhances Project Efficiency with Fieldwire by Hilti Deployment
EIN Presswire
·
April 29, 2025
Crystal Structures adopts new Fieldwire by Hilti software to integrate with others in the field during installations, enhancing the overall customer experience WICHITA, KS, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- Crystal Structures, a …
Kalmar Unveils Ottawa AutoTT™, the Future of Autonomous Terminal Tractors
GlobeNewswire
·
April 29, 2025
OTTAWA, KANSAS, April 29, 2025 (GLOBE NEWSWIRE) -- Today, Kalmar, a leader in terminal tractor solutions, and autonomous systems provider, Forterra unveiled the Kalmar Ottawa AutoTT™, an autonomous terminal tractor designed to improve efficiency and safety …
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
GlobeNewswire
·
April 29, 2025
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company …